aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma (Nasdaq: ATYR) will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026 at 8:00 AM EDT.

Rhea-AI Summary

aTyr Pharma (Nasdaq: ATYR) will present at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2026 at 8:00 AM EDT. President and CEO Sanjay S. Shukla, M.D., M.S. will deliver a corporate presentation and meet one-on-one with registered investors.

A live webcast will be available on the company’s Investor section and a replay will remain on the aTyr website for at least 90 days.

Argus Feb 18 session

+1.14% close to close Open Argus

Details

News Market Reaction – ATYR

On Feb 18, the day this news came out, ATYR closed 1.14% above the previous close.

Data tracked by StockTitan Argus for the Feb 18 session.

Key Figures

Conference dates: March 8–11, 2026 Presentation date: Wednesday, March 11, 2026 Presentation time: 8:00 am EDT +1 more

Conference dates

March 8–11, 2026

Leerink Partners Global Healthcare Conference schedule

Presentation date

Wednesday, March 11, 2026

Scheduled corporate presentation

Presentation time

8:00 am EDT

Leerink conference presentation slot

Replay availability

90 days

Webcast replay available on company website

Historical Context

5 past events · Latest: Feb 03

5 events

1. Feb 03

   Regulatory meeting plan

   24h Move

   -1.0%

   FDA Type C meeting scheduled after Phase 3 primary endpoint miss.

2. Nov 10

   Conference presentation

   24h Move

   -3.3%

   Piper Sandler healthcare conference appearance and investor meetings.

3. Nov 06

   Earnings and update

   24h Move

   -5.3%

   Q3 2025 loss and confirmation EFZO-FIT missed primary endpoint.

4. Sep 30

   Clinical data details

   24h Move

   -9.3%

   ERS Congress data showing missed primary but positive secondary measures.

5. Sep 15

   Topline Phase 3 data

   24h Move

   -83.2%

   EFZO-FIT topline results with non‑significant primary endpoint outcome.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

tRNA synthetase, fibrosis, interstitial lung disease, immunomodulator

4 terms

tRNA synthetase medical

"engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform"

tRNA synthetase is an enzyme that matches each building block of proteins (an amino acid) to its correct carrier molecule called transfer RNA (tRNA), ensuring proteins are assembled correctly in cells. Think of it as a factory worker who puts the right part onto the right delivery tray before assembly; if it fails, proteins can be made incorrectly. Investors watch these enzymes because they can be drug targets, biomarkers of disease, or sources of genetic disorders that affect a company’s therapeutic or safety profile.

fibrosis medical

"new therapies for fibrosis and inflammation"

Fibrosis is the process where excess scar tissue forms in an organ or tissue, often as a response to injury or long-term damage. This buildup can impair normal function, much like thickening insulation reduces the effectiveness of a wire. For investors, fibrosis is significant because it can signal ongoing health issues that may lead to increased medical costs or influence a company’s performance in healthcare-related sectors.

interstitial lung disease medical

"in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

immunomodulator medical

"efzofitimod, a novel biologic immunomodulator in clinical development for the treatment"

An immunomodulator is a medicine or therapy that changes how the immune system behaves—either boosting its ability to fight infections and cancer or calming it to reduce harmful inflammation. Investors watch these products because their success in clinical trials, safety and side-effect profiles, and regulatory approvals can open large markets or limit sales; think of them as tools that tweak the body’s defense system, with outcomes that strongly affect a drug maker’s future revenue and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL.

Details of the presentation appear below:

Conference: Leerink Partners Global Healthcare Conference
Date: Wednesday, March 11, 2026
Time: 8:00am EDT
Location: Miami, FL
Format: Corporate Presentation

In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharma.com.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.

Contact:

Ashlee Dunston

Sr. Director, Investor Relations and Public Affairs

adunston@atyrpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will aTyr Pharma (ATYR) present at the Leerink Partners Global Healthcare Conference?

aTyr Pharma will present on Wednesday, March 11, 2026 at 8:00 AM EDT. According to the company, the presentation is a corporate format and will occur in Miami during the conference running March 8–11, 2026.

Who will present for aTyr Pharma (ATYR) at the March 11, 2026 conference?

President and CEO Sanjay S. Shukla, M.D., M.S. will present on behalf of aTyr Pharma. According to the company, management will also be available for one-on-one investor meetings for registered attendees.

Will aTyr Pharma (ATYR) provide a webcast of its March 11, 2026 presentation?

Yes, a live webcast will be available on the company’s Investor section of its website. According to the company, a replay of the presentation will be posted on the aTyr website for at least 90 days after the event.

How can investors arrange one-on-one meetings with aTyr Pharma (ATYR) management at the conference?

Investors must be registered attendees to schedule one-on-one meetings with aTyr management. According to the company, interested investors should use attendee registration and contact investor relations for details.

Where and when is the Leerink Partners Global Healthcare Conference taking place for aTyr Pharma (ATYR)?

The conference runs March 8–11, 2026 in Miami, FL, with aTyr presenting on March 11. According to the company, the presentation is part of the conference agenda and open to registered attendees.

Where can I find the aTyr Pharma (ATYR) presentation replay after the March 11, 2026 event?

A replay will be available on the aTyr website for at least 90 days after the event. According to the company, the replay will be posted in the Investor section at the company website.